Preclinical study of CC223 as a potential anti-ovarian cancer agent

Zhenzhen Jin; Huanfu Niu; Xuenan Wang; Lei Zhang; Qin Wang; Aijun Yang

doi:10.18632/oncotarget.17753

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Preclinical study of CC223 as a potential anti-ovarian cancer agent

Zhenzhen Jin, Huanfu Niu, Xuenan Wang, Lei Zhang, Qin Wang and Aijun Yang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:58469-58479. https://doi.org/10.18632/oncotarget.17753

Metrics: PDF 1553 views | HTML 2894 views | ?

Abstract

Zhenzhen Jin1,*, Huanfu Niu1,*, Xuenan Wang1, Lei Zhang2, Qin Wang1 and Aijun Yang1

1Center for Reproductive Medicine, Affiliated Hospital of Jining Medical University, Jining, China

2Department of Pathology and Laboratory Medicine, Clinical Microarray Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA

*Co-first author

Correspondence to:

Aijun Yang, email: [email protected], [email protected]

Keywords: ovarian cancer, mTOR, CC223, signaling

Received: April 12, 2017 Accepted: April 25, 2017 Published: May 10, 2017

ABSTRACT

Aberrant activation of mTOR contributes to ovarian cancer progression. CC223 is a novel and potent mTOR kinase inhibitor. The current study tested its activity against human ovarian cancer cells. We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary human ovarian cancer cells. Further, significant apoptosis activation was observed in CC223-treated ovarian cancer cells. CC223 disrupted assembly of mTOR complex 1 (mTORC1) and mTORC2 in SKOV3 cells. Meanwhile, activation of mTORC1 and mTORC2 was almost completely blocked by CC223. Intriguingly, restoring mTOR activation by introduction of a constitutively-active Akt1 only partially inhibited CC223-induced cytotoxicity in SKOV3 cells. Further studies showed that CC223 inhibited sphingosine kinase 1 (SphK1) activity and induced reactive oxygen species (ROS) production in SKOV3 cells. At last, oral administration of CC223 potently inhibited SKOV3 xenografted tumor growth in nude mice. The results of this study imply that CC223 could be further studied as a potential anti-ovarian cancer agent.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17753

Publication Alerts

Research Papers:

Preclinical study of CC223 as a potential anti-ovarian cancer agent

Abstract